Ozempic, the blockbuster GLP-1 drug that was originally approved to treat type 2 diabetes, has now also been approved by the ...

Mounjaro vs. Ozempic: Which Is Better for Weight Loss? This article was reviewed by Craig Primack, MD, FACP, FAAP, FOMA. In one corner, we’ve got Mounjaro, and in the other, Ozempic. They’re ...

Research shows that GLP-1 receptor agonists like Ozempic can help you drop weight, manage diabetes, and even potentially lower the risk of opioid overdoses. But now, a new study finds that taking ...

Few drugs have captured public attention like Ozempic; many of us have even taken it. The type 2 diabetes medication, generically known as semaglutide, has received unprecedented attention in the ...

From heart and kidney health to addiction reduction, GLP-1 drugs like Ozempic and Mounjaro may help with more than just weight loss Steve Christo/Corbis/Corbis/Getty ...

Novo Nordisk - which manufactures Wegovy, Ozempic and Saxenda - misreported, under-reported or did not disclose funding it gave to pharmacy firms, obesity charities and other professional bodies ...

The move could mean savings for consumers. Weight loss drugs Ozempic and Wegovy have been added to the list of medications Medicare will be able to negotiate directly with drug manufacturers ...

What if a single drug could rewrite the standards of beauty that society holds dear? That's the provocative question posed by Nina King, a 27-year-old Ph.D. student whose theory on the cultural ...

There's an emerging market of "natural" supplements that claim to cause weight loss like Ozempic and similar drugs. Hunterframe - stock.adobe.com UK scientists said they have developed a low-cost ...

Obese adults who took the weekly injection lost up to 22% of their starting weight after 11 months — compared to just 14% over 15 months for semaglutide, the active ingredient in Ozempic and Wegovy.

One in eight adults in the U.S. has taken Ozempic or another type of GLP-1 drug, surveys show — and now a major new study has revealed a long list of benefits and some little-known risks.